---
document_datetime: 2024-09-10 16:02:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_en.pdf
document_name: jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9384553
conversion_datetime: 2025-12-28 03:03:35.038254
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number          | (Invented) name                                  | Strength                 | Pharmaceutical Form                | Route of Administration            | Immediate Packaging   | Content (concentration)             | Pack size                     |
|-------------------------|--------------------------------------------------|--------------------------|------------------------------------|------------------------------------|-----------------------|-------------------------------------|-------------------------------|
| EU/1/20/1525/001        | JCOVDEN                                          | --¹                      | Suspension for injection           | Intramuscular use                  | vial (glass)          | 2.5 ml (5 doses)                    | 10 multidose vials (50 doses) |
| EU/1/20/1525/002 -- --¹ | JCOVDEN                                          | --¹                      | Suspension for injection           | Intramuscular use                  | vial (glass)          | 2.5 ml (5 doses) 20 (100 authorised | multidose vials doses)        |
| ¹                       | 1 dose (0.5 mL) contains:                        |                          |                                    |                                    |                       |                                     |                               |
| Adenovirus *            | type 26 encoding the Produced in the PER.C6 TetR | SARS-CoV-2 Cell Line and | spike glycoprotein* by recombinant | (Ad26.COV2-S), not DNA technology. | less than 8.92        | log₁₀ infectious units (Inf.U).     |                               |

<!-- image -->